Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease

Saranya Ravi, Robert N. Schuck, Eleanor Hilliard, Craig R. Lee, Xuming Dai, Kaitlin Lenhart, Monte Willis, Brian C. Jensen, George A. Stouffer, Cam Patterson, Jonathan C. Schisler

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Our goal was to measure the association of CXCL5 and molecular phenotypes associated with coronary atherosclerosis severity in patients at least 65 years old. CXCL5 is classically defined as a proinflammatory chemokine, but its role in chronic inflammatory diseases, such as coronary atherosclerosis, is not well defined. We enrolled individuals who were at least 65 years old and undergoing diagnostic cardiac catheterization. Coronary artery disease (CAD) severity was quantified in each subject via coronary angiography by calculating a CAD score. Circulating CXCL5 levels were measured from plasma, and both DNA genotyping and mRNA expression levels in peripheral blood mononuclear cells were quantified via microarray gene chips. We observed a negative association of CXCL5 levels with CAD at an odds ratio (OR) of 0.46 (95% CI, 0.27–0.75). Controlling for covariates, including sex, statin use, hypertension, hyperlipidemia, obesity, self-reported race, smoking, and diabetes, the OR was not significantly affected [OR, 0.54 (95% CI, 0.31–0.96)], consistent with a protective role for CXCL5 in coronary atherosclerosis. We also identified 18 genomic regions with expression quantitative trait loci of genes correlated with both CAD severity and circulating CXCL5 levels. Our clinical findings are consistent with the emerging link between chemokines and atherosclerosis and suggest new therapeutic targets for CAD.

Original languageEnglish (US)
Pages (from-to)2895-2911
Number of pages17
JournalAmerican Journal of Pathology
Volume187
Issue number12
DOIs
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Coronary Artery Disease
Odds Ratio
Chemokines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Quantitative Trait Loci
Cardiac Catheterization
Hyperlipidemias
Oligonucleotide Array Sequence Analysis
Coronary Angiography
Blood Cells
Atherosclerosis
Chronic Disease
Obesity
Smoking
Hypertension
Phenotype
Messenger RNA
DNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Ravi, S., Schuck, R. N., Hilliard, E., Lee, C. R., Dai, X., Lenhart, K., ... Schisler, J. C. (2017). Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease. American Journal of Pathology, 187(12), 2895-2911. https://doi.org/10.1016/j.ajpath.2017.08.006

Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease. / Ravi, Saranya; Schuck, Robert N.; Hilliard, Eleanor; Lee, Craig R.; Dai, Xuming; Lenhart, Kaitlin; Willis, Monte; Jensen, Brian C.; Stouffer, George A.; Patterson, Cam; Schisler, Jonathan C.

In: American Journal of Pathology, Vol. 187, No. 12, 01.12.2017, p. 2895-2911.

Research output: Contribution to journalArticle

Ravi, S, Schuck, RN, Hilliard, E, Lee, CR, Dai, X, Lenhart, K, Willis, M, Jensen, BC, Stouffer, GA, Patterson, C & Schisler, JC 2017, 'Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease', American Journal of Pathology, vol. 187, no. 12, pp. 2895-2911. https://doi.org/10.1016/j.ajpath.2017.08.006
Ravi, Saranya ; Schuck, Robert N. ; Hilliard, Eleanor ; Lee, Craig R. ; Dai, Xuming ; Lenhart, Kaitlin ; Willis, Monte ; Jensen, Brian C. ; Stouffer, George A. ; Patterson, Cam ; Schisler, Jonathan C. / Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease. In: American Journal of Pathology. 2017 ; Vol. 187, No. 12. pp. 2895-2911.
@article{ea224882b0a14e46ab1279a0aa441f41,
title = "Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease",
abstract = "Our goal was to measure the association of CXCL5 and molecular phenotypes associated with coronary atherosclerosis severity in patients at least 65 years old. CXCL5 is classically defined as a proinflammatory chemokine, but its role in chronic inflammatory diseases, such as coronary atherosclerosis, is not well defined. We enrolled individuals who were at least 65 years old and undergoing diagnostic cardiac catheterization. Coronary artery disease (CAD) severity was quantified in each subject via coronary angiography by calculating a CAD score. Circulating CXCL5 levels were measured from plasma, and both DNA genotyping and mRNA expression levels in peripheral blood mononuclear cells were quantified via microarray gene chips. We observed a negative association of CXCL5 levels with CAD at an odds ratio (OR) of 0.46 (95{\%} CI, 0.27–0.75). Controlling for covariates, including sex, statin use, hypertension, hyperlipidemia, obesity, self-reported race, smoking, and diabetes, the OR was not significantly affected [OR, 0.54 (95{\%} CI, 0.31–0.96)], consistent with a protective role for CXCL5 in coronary atherosclerosis. We also identified 18 genomic regions with expression quantitative trait loci of genes correlated with both CAD severity and circulating CXCL5 levels. Our clinical findings are consistent with the emerging link between chemokines and atherosclerosis and suggest new therapeutic targets for CAD.",
author = "Saranya Ravi and Schuck, {Robert N.} and Eleanor Hilliard and Lee, {Craig R.} and Xuming Dai and Kaitlin Lenhart and Monte Willis and Jensen, {Brian C.} and Stouffer, {George A.} and Cam Patterson and Schisler, {Jonathan C.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.ajpath.2017.08.006",
language = "English (US)",
volume = "187",
pages = "2895--2911",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease

AU - Ravi, Saranya

AU - Schuck, Robert N.

AU - Hilliard, Eleanor

AU - Lee, Craig R.

AU - Dai, Xuming

AU - Lenhart, Kaitlin

AU - Willis, Monte

AU - Jensen, Brian C.

AU - Stouffer, George A.

AU - Patterson, Cam

AU - Schisler, Jonathan C.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Our goal was to measure the association of CXCL5 and molecular phenotypes associated with coronary atherosclerosis severity in patients at least 65 years old. CXCL5 is classically defined as a proinflammatory chemokine, but its role in chronic inflammatory diseases, such as coronary atherosclerosis, is not well defined. We enrolled individuals who were at least 65 years old and undergoing diagnostic cardiac catheterization. Coronary artery disease (CAD) severity was quantified in each subject via coronary angiography by calculating a CAD score. Circulating CXCL5 levels were measured from plasma, and both DNA genotyping and mRNA expression levels in peripheral blood mononuclear cells were quantified via microarray gene chips. We observed a negative association of CXCL5 levels with CAD at an odds ratio (OR) of 0.46 (95% CI, 0.27–0.75). Controlling for covariates, including sex, statin use, hypertension, hyperlipidemia, obesity, self-reported race, smoking, and diabetes, the OR was not significantly affected [OR, 0.54 (95% CI, 0.31–0.96)], consistent with a protective role for CXCL5 in coronary atherosclerosis. We also identified 18 genomic regions with expression quantitative trait loci of genes correlated with both CAD severity and circulating CXCL5 levels. Our clinical findings are consistent with the emerging link between chemokines and atherosclerosis and suggest new therapeutic targets for CAD.

AB - Our goal was to measure the association of CXCL5 and molecular phenotypes associated with coronary atherosclerosis severity in patients at least 65 years old. CXCL5 is classically defined as a proinflammatory chemokine, but its role in chronic inflammatory diseases, such as coronary atherosclerosis, is not well defined. We enrolled individuals who were at least 65 years old and undergoing diagnostic cardiac catheterization. Coronary artery disease (CAD) severity was quantified in each subject via coronary angiography by calculating a CAD score. Circulating CXCL5 levels were measured from plasma, and both DNA genotyping and mRNA expression levels in peripheral blood mononuclear cells were quantified via microarray gene chips. We observed a negative association of CXCL5 levels with CAD at an odds ratio (OR) of 0.46 (95% CI, 0.27–0.75). Controlling for covariates, including sex, statin use, hypertension, hyperlipidemia, obesity, self-reported race, smoking, and diabetes, the OR was not significantly affected [OR, 0.54 (95% CI, 0.31–0.96)], consistent with a protective role for CXCL5 in coronary atherosclerosis. We also identified 18 genomic regions with expression quantitative trait loci of genes correlated with both CAD severity and circulating CXCL5 levels. Our clinical findings are consistent with the emerging link between chemokines and atherosclerosis and suggest new therapeutic targets for CAD.

UR - http://www.scopus.com/inward/record.url?scp=85034262890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034262890&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2017.08.006

DO - 10.1016/j.ajpath.2017.08.006

M3 - Article

VL - 187

SP - 2895

EP - 2911

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 12

ER -